title: Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
abstract: Dub3 is a deubiquitinating enzyme. It is highly expressed in tumor-derived cell lines and has an established role in tumor proliferation. However, the role of Dub3 in human ovarian cancer remains unclear. Expression of Dub3 was evaluated in ovarian cancer tissues and cell lines by immunohistochemistry and Western blot analysis. The relationship between Dub3 expression and clinicopathological characteristics was analyzed. Using RNA interference, the effects of Dub3 on cell proliferation and apoptosis were investigated in ovarian cancer cell line. All normal ovary tissues exhibited very little or no Dub3 immunoreactivity. High levels of Dub3 expression were examined by immunohistochemical analysis in 13.3% of cystadenomas, in 30.0% of borderline tumors, and in 58.9% of ovarian carcinomas, respectively. Dub3 expression was significantly associated with lymph node metastasis and clinical staging (P<0.05). Multivariate survival analysis indicated that Dub3 expression was an independent prognostic indicator of the survival of patients with ovarian cancer. Furthermore, the expression of Cdc25A was closely correlated with that of Dub3 in cancer cells and tissues. Knockdown of Dub3 could inhibit the proliferation of ovarian cancer cells and increase cell apoptosis. These data indicate that the Dub3 might be a valuable biomarker for the prediction of ovarian cancer prognosis and Dub3 inhibition might be a potential strategy for ovarian cancer treatment.
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, 210009 Nanjing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhou
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, 210009 Nanjing, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Shu
authors.affiliation: State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, 210009 Nanjing, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Xi
authors.affiliation: Department of Pathology, Zhongda Hospital, Southeast University, 210009 Nanjing, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Su
authors.affiliation: Jiangsu Center for Safety Evaluation of Drugs, School of Pharmaceutical Sciences, Nanjing Tech University, 210009 Nanjing, China. Electronic address: jansens2004@sina.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
mesh_terms: D014408:Biomarkers, Tumor; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D010450:Endopeptidases / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D006801:Humans; D008223:Lymphoma; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D020687:cdc25 Phosphatases / Q000235:genetics / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C517004:CDC25A protein, human; D020687:cdc25 Phosphatases; D010450:Endopeptidases; C484854:USP17L2 protein, human
keywords: CDC25A; Dub3; Ovarian cancer; Proliferation